Donepezil for the treatment of agitation in Alzheimer's disease

Howard, Robert J. and Juszczak, Edmund and Ballard, Clive G. and Bentham, Peter and Brown, Richard G. and Bullock, Roger A. and Burns, Alistair and Holmes, Clive and Jacoby, Robin and Johnson, Tony and Knapp, Martin R J. and Lindesay, James and O'Brien, John T. and Wilcock, Gordon and Katona, Cornelius and Jones, Roy W. and DeCesare, Julia and Rodger, Michaela (2007) Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357 (14). pp. 1382-1392. ISSN 0028-4793 . (The full text of this publication is not available from this repository)

The full text of this publication is not available from this repository. (Contact us about this Publication)
Official URL
http://dx.doi.org/10.1056/NEJMoa066583

Abstract

Background Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear. Methods We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks. The primary outcome was a change in the score on the Cohen-Mansfield Agitation Inventory (CMAI) (on a scale of 29 to 203, with higher scores indicating more agitation) at 12 weeks. Results There was no significant difference between the effects of donepezil and those of placebo on the basis of the change in CMAI scores from baseline to 12 weeks (estimated mean difference in change [the value for donepezil minus that for placebo], -0.06; 95% confidence interval [CI], -4.35 to 4.22). Twenty-two of 108 patients (20.4%) in the placebo group and 22 of 113 (19.5%) in the donepezil group had a reduction of 30% or greater in the CMAI score (the value for donepezil minus that for placebo, -0.9 percentage point; 95% CI, -11.4 to 9.6). There were also no significant differences between the placebo and donepezil groups in scores for the Neuropsychiatric Inventory, the Neuropsychiatric Inventory Caregiver Distress Scale, or the Clinician's Global Impression of Change. Conclusions In this 12-week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer's disease.

Item Type: Article
Additional information: No DOI/References/Full text/ Official URL or keywords available
Subjects: R Medicine
Divisions: Faculties > Science Technology and Medical Studies > Kent Institute of Medicine and Health Sciences (KIMHS)
Depositing User: Maureen Cook
Date Deposited: 19 Mar 2008 09:07
Last Modified: 17 Jun 2014 15:49
Resource URI: http://kar.kent.ac.uk/id/eprint/2326 (The current URI for this page, for reference purposes)
  • Depositors only (login required):